better facilitate inspection readiness and ensure patient safety and product efficacy.

Step 1: Understand Regulatory Landscape and Product Classification

The first step to GMP compliance for combination products is a thorough understanding of regulatory definitions, classifications, and applicable GMP expectations. Combination products typically consist of a drug component combined with a device, such as a pre-filled syringe (parenteral), an inhaler with a drug formulation, or a topical product with a device applicator.

Key Actions:

• Identify Product Classification: Determine whether the product will be regulated primarily as a drug, device, or under a combination product pathway. In the US, the FDA’s Office of Combination Products coordinates assignment (see FDA 21 CFR Part 3). In the EU, Regulation (EU) 2017/745 on medical devices and Regulation (EC) No 726/2004 on medicinal products govern classification.
• Determine Applicable GMP Requirements: Understand that combination products subject to drug regulation must comply with 21 CFR Parts 210 and 211 for drug GMP, while device aspects invoke ISO 13485 and device-specific requirements. EU GMP Volume 4 outlines pharmaceutical GMP obligations for drug components, and Annex 15 addresses qualification and validation for sterile components common in parenteral combination products.
• Assess Dosage Form-Specific Controls: Each dosage form (solid oral tablets, capsules, sterile injectables, topical forms, inhalation products) brings unique GMP challenges requiring tailored control strategies for formulation, equipment, environment, and process validation.

Failing to classify correctly at the outset leads to compliance gaps and inspection deficiencies. Early regulatory consultation and classification confirmation mitigate project delays and facilitate streamlined development and manufacturing compliance.

Step 2: Develop Integrated GMP Documentation and Quality Systems

Effective GMP adherence at the drug–device interface centers on comprehensive and integrated quality management systems (QMS). These systems must encompass all aspects of drug and device manufacture, combining controls to ensure batch consistency, sterility assurance where applicable, traceability, and controlled change management.

Key Actions:

• Establish Combined Quality Agreements: For combination products sourced or jointly manufactured, quality agreements should detail roles, responsibilities, GMP standards, batch release criteria, handling of deviations, complaints, and recalls.
• Develop Unified Standard Operating Procedures (SOPs): SOPs should incorporate practices from pharmaceutical GMP and device quality requirements. Particular attention should be paid to cross-training personnel in hygiene, gowning, and aseptic technique when manufacturing sterile injectables or device assembly in cleanroom environments.
• Implement Risk Management and Change Control: According to ICH Q9 (Quality Risk Management) and Annex 15, systematically assess all process changes, equipment upgrades, and supplier modifications impacting either drug or device components. A combined change control system supports regulatory expectations for robust lifecycle management.
• Ensure Traceability and Serialization: For accountability, batch records must integrate drug component lot numbers with device part serials or unique device identifiers (UDI). This traceability supports pharmacovigilance and post-market surveillance.

By unifying quality systems under a harmonized GMP-based framework, organizations enhance compliance visibility and provide inspectors with a clear audit trail demonstrating integrated control at the drug–device interface.

Step 3: Control Dosage Form-Specific Manufacturing Processes for Combination Products

Each dosage form within combination products demands a focused approach to GMP-controlled manufacturing. These processes include tablet manufacturing, capsule GMP operations, sterile injectables filling, topical production, and inhalation product assembly. Understanding dosage-form–specific challenges ensures compliance and product integrity.

Solid Oral Dosage Forms (Tablets and Capsules)

For combination products incorporating tablets or capsules, such as drug-device blister packs or capsule-inhaler assemblies, GMP must govern:

• Formulation Precision: Strict control of excipients, active pharmaceutical ingredient (API) potency, and homogeneity through validated mixing and blending processes.
• Tablet Manufacturing: Ensuring tablet hardness, disintegration, and dissolution meet specifications. Critical process parameters include compression force, granule moisture content, and lubricant uniformity.
• Capsule GMP: Capsule filling accuracy, shell composition compliance, and environmental controls to prevent contamination and moisture ingress during production and packaging.
• Device Interface: Assembly into devices or blisters must preserve dosage form integrity without compromising device functionality.

Sterile Parenteral Dosage Forms

Parenteral delivery systems such as pre-filled syringes or infusion pumps require rigorous aseptic processing controls aligned with sterility assurance standards:

• Cleanroom Classification: Manufacturing must occur in Grade A/B environments for aseptic filling per EMA Annex 1 harmonized with PIC/S PE 009 requirements.
• Media Fill Validation: Simulated aseptic process validation demonstrates process capability and operator aseptic technique under representative conditions, a critical GMP expectation.
• Container Closure Systems: Qualification and integrity testing of device components (syringe barrels, needles, stoppers) to prevent contamination and maintain sterility throughout shelf life.
• Environmental Monitoring: Continuous monitoring of viable and non-viable particulates ensures maintenance of aseptic conditions during batch processing.

Topical and Inhalation Dosage Forms

Topical products and inhalation devices incorporate both pharmaceutical and device GMP concerns:

• Topicals: Manufacturing involves ointment or cream formulation, achieving uniform active ingredient distribution, microbial limits testing, packaging compatibility with applicators, and environmental control to prevent contamination during filling and sealing.
• Inhalation Products: DPI (dry powder inhalers) and MDI (metered dose inhalers) require verification of dose uniformity, device actuation reliability, and particle size distribution impacting pulmonary delivery efficacy.
• Device Assembly and Integration: Device components must be manufactured in controlled environments, with biocompatibility and functionality verified during comprehensive device validation.

Each dosage form demands dedicated validation protocols capturing critical process parameters, in-process controls, and finished product testing to assure product quality and patient safety.

Step 4: Validate and Qualify Combined Manufacturing Processes and Facilities

Validation and qualification form the cornerstone for GMP compliance at the drug–device interface. Combination product manufacturing requires a full validation lifecycle encompassing process, equipment, utilities, and facilities that support both pharmaceutical and device components.

Key Actions:

• Facility and Equipment Qualification: Carry out Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) for all equipment and manufacturing suites, meeting requirements outlined in EU GMP Annex 15. Special attention is required for aseptic processing equipment in sterile injectables manufacturing.
• Process Validation: Implement process validation protocols demonstrating reproducibility within controlled parameters for each dosage form and device assembly process. Sterile combination product processes require media fills and sterility validation per Annex 1.
• Cleaning Validation: Due to the complex interfacing with medical device components, validate cleaning procedures for equipment handling both drug and device materials to prevent cross-contamination and ensure GMP compliance.
• Computerized System Validation: Validate software controlling devices or manufacturing systems, ensuring data integrity and compliance with 21 CFR Part 11, EU GMP Annex 11, and PIC/S guidelines.

Documentation of all validation activities, protocols, and reports must be meticulously maintained for inspection readiness and lifecycle management.

Step 5: Implement Robust Control and Monitoring of Combination Product Batches

Batch control for combination products is complex due to the dual nature of drug and device components. This step ensures that manufacturing outputs conform consistently to predefined quality specifications.

Key Actions:

• Batch Record Integration: Create comprehensive batch manufacturing records (BMRs) reflecting all processes for drug formulation, device assembly, and final combination product packaging. Records must log component lot numbers, process parameters, environmental data, and release criteria.
• In-Process Controls (IPC): Monitor critical parameters such as tablet weight variance, capsule fill accuracy, sterile fill volumes, dose delivery accuracy for inhalation products, and device functional tests during production.
• Finished Product Testing: Perform a full complement of analytical testing: assay, purity, sterility, particulate matter, dissolution, and device performance tests per established specifications.
• Environmental and Personnel Monitoring: Maintain tight controls on environmental conditions for aseptic or clean manufacturing areas including particle counts, microbial limits, and surface monitoring. Personnel gowning and training records must be up to date and demonstrated through periodic assessments.
• Batch Release Procedures: Qualified persons or Responsible Persons must review all documentation and testing outcomes before release. In the EU and UK, compliance with Annex 16 is essential. The US follows FDA requirements for batch certification and GMP compliance.

Integration of batch control ensures traceability, compliance, and quality assurance vital for patient safety and regulatory acceptance.

Step 6: Prepare for GMP Inspections and Regulatory Submissions

Combination products require proactive preparation for regulatory inspections and dossier submissions. Because these products cross traditional drug and device boundaries, inspection teams may include multiple inspectors from diverse backgrounds.

Key Actions:

• Conduct Internal Audits: Plan and execute GMP audits focused on areas critical to combined manufacturing processes. Pay particular attention to sterile manufacturing controls, device assembly, and integrated QMS effectiveness.
• Maintain Inspection Readiness: Ensure that documentation, validation, training records, and deviation investigations are current and organized. Prepare personnel to discuss drug-device interface controls, cleaning validation, and environmental monitoring.
• Compile Regulatory Submissions: For marketing authorizations, submissions should clearly delineate drug and device data modules per US FDA’s combination product guidelines and European Medical Device Regulation (MDR) annexes related to drug-device GMP compliance.
• Respond Effectively to Findings: Establish CAPA systems to address inspection observations promptly and comprehensively to maintain regulatory trust and continued product availability.

Successful regulatory navigation depends on demonstrable control of the product lifecycle, integrating GMP principles with cross-functional collaboration among regulatory, quality, and manufacturing teams.

Summary: Harmonizing GMP Across Drug and Device Components in Combination Products

Following a structured, step-by-step approach to GMP compliance at the drug product interface ensures that complex combination products meet rigorous quality and regulatory expectations in the US, UK, and EU markets. Key components include accurate product classification, integrated quality systems, dosage-form–specific manufacturing controls, thorough validation and qualification, rigorous batch oversight, and diligent inspection preparedness.

Pharmaceutical professionals must maintain constant vigilance on evolving regulatory guidance, including FDA’s combination product framework, EMA’s EU GMP Volume 4 and Annexes, MHRA standards, PIC/S recommendations, WHO GMP, and ICH guidelines such as Q7 (API GMP), Q8 (pharmaceutical development), Q9 (risk management), and Q10 (pharmaceutical quality system). This ensures combination products incorporating tablets, capsules, sterile injectables, topicals, or inhalation devices fulfill patient safety, product efficacy, and commercial requirements.

By embedding robust GMP practices and embracing cross-disciplinary collaboration, manufacturers can achieve compliant, effective, and safe combination products ready for global markets and inspection scrutiny.